VistaGen Therapeutics, Inc. (VTGN) — Financial statements
Income statement, balance sheet, and cash flow for VistaGen Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2026 | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 1↑161.1% | 0.49↓54.3% | 1↑568.7% | -0.23↓120.5% | 1 | |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | 0.00↓100.0% | 0.49↓54.3% | 1↑568.7% | -0.23↓120.5% | 1 | |
| Operating Expenses | ||||||
| R&D Expenses | 55↑39.6% | 39↑96.7% | 20↓54.9% | 44↑25.3% | 35 | |
| General & Administrative Expenses | 18↑7.8% | 17↑21.5% | 14↓4.1% | 15↑40.3% | 10 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00↓100.0% | 3 | |
| SG&A Expenses | 18↑7.8% | 17↑21.5% | 14↓4.1% | 15↑10.7% | 13 | |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00↓100.0% | 0.23 | |
| Operating Expenses | 73↑30.0% | 56↑65.6% | 34↓42.3% | 59↑20.8% | 49 | |
| Total Costs & Expenses | 0.00↓100.0% | 56↑65.6% | 34↓42.3% | 59↑20.8% | 49 | |
| Operating Results | ||||||
| Operating Income | -72↓28.9% | -56↓69.5% | -33↑44.3% | -59↓24.0% | -48 | |
| Depreciation & Amortization | 0.00↓100.0% | 0.64↑11.8% | 0.57↑6.8% | 0.53↓25.2% | 0.71 | |
| EBITDA | -72↓30.3% | -55↓70.5% | -32↑44.7% | -59↓24.8% | -47 | |
| EBIT | 0.00↑100.0% | -56↓69.5% | -33↑44.3% | -59↓24.1% | -48 | |
| Interest & Other Income | ||||||
| Net Interest Income | 0.00↓100.0% | 5↑36.0% | 3↑12788.5% | 0.03↑30.0% | 0.02 | |
| Interest Income | 0.00↓100.0% | 5↑36.0% | 3↑6738.8% | 0.05↑145.0% | 0.02 | |
| Interest Expense | 0.00 | 0.00 | 0.00↓100.0% | 0.02 | 0.00 | |
| Non-Operating Income | 0.00 | 0.00 | 0.00↓100.0% | 0.03↑241.7% | -0.02 | |
| Other Income / Expenses | 2↓46.3% | 5↑24.5% | 4↑13988.5% | 0.03↑30.7% | 0.02 | |
| Income Before Tax | -70↓35.5% | -51↓75.1% | -29↑50.4% | -59↓24.0% | -48 | |
| Income Tax Expense | 0.01↑0.0% | 0.01↑75.0% | 0.00↓33.3% | 0.01↑76.5% | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -70↓35.5% | -51↓75.1% | -29↑50.4% | -59↓24.0% | -48 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -70↓35.5% | -51↓75.1% | -29↑50.4% | -59↓24.0% | -48 | |
| Bottom-Line Net Income | -70↓35.5% | -51↓75.1% | -29↑50.4% | -59↓21.6% | -49 | |
| EPS (Basic) | -1.83↓9.6% | -1.67↓9.9% | -1.52↑82.1% | -8.51↓15.3% | -7.38 | |
| EPS (Diluted) | -1.83↓9.6% | -1.67↓9.9% | -1.52↑82.1% | -8.51↓15.3% | -7.38 | |
| Weighted Average Shares | 38↑24.0% | 31↑58.7% | 19↑178.1% | 7↑5.4% | 7 | |
| Weighted Average Diluted Shares | 38↑24.0% | 31↑58.7% | 19↑178.1% | 7↑5.4% | 7 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.